Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Blood Purif ; 47 Suppl 2: 19-24, 2019.
Article in English | MEDLINE | ID: mdl-30943515

ABSTRACT

BACKGROUND/AIM: In this study, we compared the dialysis efficiency, oxidative stress, and nutritional conditions between predilution on-line hemodiafiltration (pre-OL-HDF) and conventional hemodialysis (HD) using a super-flux dialyzer (CHD). METHOD: This was a crossover study of 38 maintenance HD patients. All patients were treated with CHD for the first 4 months (1st CHD period), then were switched to pre-OL-HDF for 4 months (pre-OL-HDF period), and were returned to CHD for the next 4 months (2nd CHD period). RESULTS: We found no significant difference in the removal ratio of small uremic substances or the indices of inflammation or nutritional states between the pre-OL-HDF and CHD periods. However, we found higher removal of ß2 micro-globulin in the pre-OL-HDF period, and the human mercapto-albumin (Alb)/human serum Alb ratio was significantly higher in the pre-OL-HDF period. CONCLUSION: Treatment with pre-OL-HDF enabled enhanced removal of middle molecule uremic toxins and better Alb redox than did CHD.


Subject(s)
Hemodiafiltration/methods , Oxidative Stress , Serum Albumin, Human/isolation & purification , Sulfhydryl Compounds/isolation & purification , Toxins, Biological/isolation & purification , Aged , Cross-Over Studies , Female , Hemodiafiltration/economics , Hemodiafiltration/instrumentation , Humans , Inflammation/blood , Kidney Diseases/blood , Kidney Diseases/therapy , Male , Middle Aged , Oxidation-Reduction , Serum Albumin, Human/analysis , Sulfhydryl Compounds/analysis , Toxins, Biological/blood
2.
Springerplus ; 3: 72, 2014.
Article in English | MEDLINE | ID: mdl-24555174

ABSTRACT

A 65-year-old Japanese male with therapy-related myelodysplastic syndrome was admitted for unrelated cord blood transplantation. A cord blood unit from a male donor was obtained from the Japan Cord Blood Bank Network. The patient then received a conditioning regimen consisting of fludarabine, intravenous busulfan, and total body irradiation. Successful engraftment was obtained. The bone marrow examination on day 28 revealed trilineage engraftment, and chimerism analysis by variable number of tandem repeat polymerase chain reaction confirmed complete donor chimerism. At that time, conventional cytogenetics of the bone marrow aspirate showed 20 out of 20 metaphases with the 47, XXY karyotype characteristic of Klinefelter syndrome. Klinefelter syndrome is the most common genetic cause of human male infertility with a reported prevalence of 0.1-0.2% in the general population. In Japan Cord Blood Bank Network, there is no informed consent from parents about the possibility that post-unrelated cord blood transplantation patient evaluation may reveal donor-origin inherited diseases including cytogenetic abnormality. It is desirable to have opportunities in Japan discussing whether parents will be notified of the possibility that post-unrelated cord blood transplantation evaluation may reveal donor-derived illness incidentally.

3.
Rinsho Ketsueki ; 54(3): 311-5, 2013 Mar.
Article in Japanese | MEDLINE | ID: mdl-23676649

ABSTRACT

A 62-year-old woman with acute lymphoblastic leukemia in first complete remission was treated with unrelated cord blood transplantation, but exhibited primary graft failure. She then underwent HLA-haploidentical peripheral blood stem cell transplantation from her daughter. The conditioning regimen consisted of fludarabine 30 mg/m(2)/day for 6 days, intravenous busulfan 3.2 mg/kg/day for 2 days, and thymoglobulin 1 mg/kg/day for 2 days. Voriconazole was administered to prevent fungal infections. The patient achieved prompt hematopoietic recovery. Fever was observed 21 days after the second transplant, followed by sigmoid colon perforation and a liver space occupying lesion (SOL). A filamentous fungus was detected in a percutaneous biopsy of the liver SOL. In spite of changing the antifungal drug from voriconazole to liposomal amphotericin B, the patient died on day 41. The fungus was identified as Mucor indicus, a type of zygomycete. Although Mucor indicus inhabits soil, an infectious disease is extremely rare, and breakthrough infection after voriconazole prophylaxis had not been reported until now. It is mandatory to consider preventive antifungal treatment for drug-resistant fungal infectious diseases in patients after neutrophilic recovery with a strongly immunocompromised state after a HLA-haploidentical transplant.


Subject(s)
Graft vs Host Disease/drug therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Mucor/isolation & purification , Vidarabine/analogs & derivatives , Zygomycosis/drug therapy , Female , Humans , Middle Aged , Treatment Outcome , Vidarabine/administration & dosage , Vidarabine/therapeutic use , Zygomycosis/etiology
4.
Acta Haematol ; 129(2): 83-9, 2013.
Article in English | MEDLINE | ID: mdl-23171834

ABSTRACT

The 8p11 myeloproliferative syndrome is a rare neoplasm associated with chromosomal translocations involving the fibroblast growth factor receptor 1 (FGFR1) gene located at chromosome 8p11-12. FGFR1 encodes a transmembrane receptor tyrosine kinase. The resultant fusion proteins are constitutively active tyrosine kinases that drive the proliferation of hematopoietic cells, whose uncontrolled growth can present as a myeloproliferative neoplasm. We report here the case of a 50-year-old man harboring the t(8;22)(p12;q11) chromosomal translocation in cells from both bone marrow and lymph nodes. He presented with acute leukemia and lymphoma with trilineage features. A novel mRNA in-frame fusion between exon 4 of the breakpoint cluster region (BCR) gene at chromosome 22q11 and exon 9 of FGFR1 gene on chromosome 8p11-12 was identified by reverse transcription polymerase chain reaction analysis and was confirmed by DNA sequencing. Because the patient was refractory to chemotherapy, cord blood transplantation was performed in progressive disease. It resulted in a successful outcome in which cytogenetic complete remission has been maintained for 2 years till date.


Subject(s)
Fetal Blood/transplantation , Myeloproliferative Disorders/genetics , Oncogene Proteins, Fusion/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Proto-Oncogene Proteins c-bcr/genetics , Receptor, Fibroblast Growth Factor, Type 1/genetics , Humans , Male , Middle Aged , Translocation, Genetic
5.
Int J Hematol ; 97(1): 139-43, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23264126

ABSTRACT

The small cell variant of anaplastic large cell lymphoma (ALCL) presents in a nearly identical manner to the more common ALK(+) primary ALCL, with the exception that it is more frequently associated with leukemic involvement, and the prognosis has been reported to be poor. We report a 40-year-old Japanese male who was diagnosed with small cell variant ALCL with peripheral blood involvement stage IVB, age-adjusted international prognostic index 3. Conventional cytogenetics of the bone marrow aspirate specimen showed abnormal metaphases with the following karyotype: 47, XY, +X, t(2;5)(p23;q35). The patient was treated with acute lymphoblastic leukemia-oriented intensive chemotherapy. He underwent allogeneic peripheral blood stem cell transplantation from his HLA-DR1 locus mismatch sister. Prior to transplant, the patient had residual lymphadenopathy considered to be in partial remission. As of August 2012, the patient has achieved 18 months of continuous complete remission (CCR), with a Karnofsky score of 100 %. We have identified a total of seven cases of small cell variant ALCL treated with allogeneic hematopoietic stem cell transplantation (HSCT) in the literature. Of these, no relapse was reported, and four patients were CCR more than 1 year. Allogeneic HSCT appears to represent a promising treatment option for small cell variant ALCL.


Subject(s)
Lymphoma, Non-Hodgkin/therapy , Peripheral Blood Stem Cell Transplantation , Adult , Bone Marrow/pathology , Humans , Lymphocytes/pathology , Lymphoma, Non-Hodgkin/diagnosis , Male , Transplantation Conditioning , Transplantation, Homologous , Treatment Outcome
6.
Int J Hematol ; 96(5): 657-63, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22976114

ABSTRACT

We report the results of unrelated cord blood transplantation (UCBT) for patients with adult T-cell leukemia/lymphoma (ATLL) conducted in our single institute. Ten patients with ATLL (nine acute and one lymphoma-type) received UCBT during the period from August 2003 to July 2011. The median age at the time of diagnosis of ATLL was 51 years (range 37-64). The median period from diagnosis of ATLL to UCBT was 130 days (range 94-344). Conditioning regimens were myeloablative for six and reduced intensity for four. The median number of infused nucleated cells and CD34 positive cells were 2.52 × 10(7)/kg and 1.04 × 10(5)/kg, respectively. There was no engraftment failure. Three patients developed grade II acute graft versus host disease, and four developed grade III. The estimated 2-year overall survival was 40 % (95 % CI 12-67 %). Four of six chemosensitive patients prior to UCBT survived for 1035, 793, 712, and 531 days post-UCBT, respectively. There were no survivors among the four chemorefractory patients prior to UCBT. Our data indicates that UCBT is feasible and provides long-term survival in patients with chemosensitive ATLL.


Subject(s)
Cord Blood Stem Cell Transplantation , Leukemia-Lymphoma, Adult T-Cell/mortality , Leukemia-Lymphoma, Adult T-Cell/therapy , Unrelated Donors , Acute Disease , Adult , Disease-Free Survival , Female , Graft vs Host Disease/etiology , Graft vs Host Disease/mortality , Graft vs Host Disease/therapy , Humans , Male , Middle Aged , Retrospective Studies , Survival Rate , Transplantation, Homologous
7.
Kansenshogaku Zasshi ; 86(6): 773-7, 2012 Nov.
Article in Japanese | MEDLINE | ID: mdl-23367854

ABSTRACT

We present a case of amebic colitis and liver abscess complicated by acute myeloid leukemia (AML) with high serum procalcitonin (PCT). A 61-year-old Japanese man seen at our hospital for severe diarrhea and high fever was found to have multiple ulcers in the transverse and sigmoid colon and rectum by colonoscopy and biopsies were conducted. Immature leukocytes with mild anemia and thrombocytopenia were seen in peripheral blood, necessitating bone marrow aspiration and biopsy that yielded a diagnosis of AML (FAB M4Eo). Serum C-reactive protein and PCT were extremely elevated. Blood cultures for bacteria and fungi were negative. Multiple low-density areas in the liver were found in abdominal computed tomography. Histological colon biopsy findings revealed amebic colitis, strongly suggesting amebic liver abscess. Metronidazole treatment was initiated for amebiasis and subsequent standard chemotherapy for AML was followed after fever was lowered. Hematological and cytogenetic CR was maintained with good clinical condition. Few case reports have been published in Japan to date on amebic colitis and liver abscess complicated by AML and no reports have been made on PCT elevation caused by amebiasis. In conclusion, differential diagnosis of amebiasis is necessary in addition to that of bacterial or fungal infection in serum PCT elevation.


Subject(s)
Calcitonin/blood , Dysentery, Amebic/complications , Leukemia, Myeloid, Acute/complications , Liver Abscess, Amebic/complications , Protein Precursors/blood , Calcitonin Gene-Related Peptide , Dysentery, Amebic/blood , Humans , Leukemia, Myeloid, Acute/blood , Liver Abscess, Amebic/blood , Male , Middle Aged
8.
Int J Hematol ; 89(4): 452-459, 2009 May.
Article in English | MEDLINE | ID: mdl-19353237

ABSTRACT

To investigate the association between hepatitis C virus (HCV) and B cell proliferation, we searched for the clonal B cells by flow cytometric analysis of the surface immunoglobulin kappa (kappa):lambda (lambda) light chain ratios of the circulating B (CD19+) cells in 240 HCV-positive patients and 150 negative controls with liver diseases. Clonal B cells with light chain restriction (kappa:lambda ratio >3:1 or <1:2) were analyzed for CD5 expression and the presence of monoclonal immunoglobulin heavy-chain (IGH) gene rearrangements and the t(14;18) chromosomal translocation. Clonal B cells were detected in 7 cases with HCV (2.9%), but was never detected in the controls (p < 0.05). Of the 7 cases, all had monoclonal IGH gene rearrangements and one had the t(14;18) chromosomal translocation. These HCV-related clonal B cells are not uniform in the intensity of CD5 expression and showed no increase in the frequencies of CD5+ population compared with non-clonal B cells. No "chronic lymphocytic leukemia-phenotype" cells were found. The loss of clonality was observed in 2 cases treated with interferon and in one case treated with splenectomy. The longitudinal study is required to determine whether these circulating clonal B cells progress to lymphoproliferative disorders in future or not.


Subject(s)
B-Lymphocytes/immunology , Hepatitis C/blood , Hepatitis C/immunology , Aged , Aged, 80 and over , Antigens, CD20/immunology , B-Lymphocytes/cytology , B-Lymphocytes/metabolism , CD5 Antigens/immunology , Case-Control Studies , Cell Movement , Female , Gene Expression Regulation , Humans , Immunoglobulin Heavy Chains/genetics , Immunoglobulin Heavy Chains/immunology , Male , Protein Transport , Proto-Oncogene Proteins c-bcl-2/metabolism , Splenectomy
9.
Int J Hematol ; 88(1): 57-63, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18465194

ABSTRACT

Periostin is a secreted protein that shares structural homology with the insect axon guidance protein fasciclin 1. Periostin is expressed predominantly in collagen-rich fibrous connective tissues that are subjected to constant mechanical stresses. We have shown previously that periostin is a novel component of subepithelial fibrosis in bronchial asthma. Here, we investigated the relationship between periostin and bone marrow (BM) fibrosis. Periostin was expressed in the stroma and stromal cells of BM fibrosis specimens and to a great extent its expression levels correlated closely to the grade of fibrosis, as estimated by silver staining. However, in the present study, we found no relationship between plasma periostin levels and the extent of BM fibrosis. We also demonstrated that periostin is secreted by human BM hTERT stromal cells and that its secretion is enhanced by TGF-beta, a cytokine produced by clonal proliferation of megakaryocytes and/or monocytes. These results indicate that periostin is a component of BM fibrosis and that it may play a role in the disease progression.


Subject(s)
Bone Marrow/metabolism , Cell Adhesion Molecules/biosynthesis , Primary Myelofibrosis/metabolism , Aged , Bone Marrow/pathology , Cell Proliferation , Female , Humans , Male , Megakaryocytes/metabolism , Megakaryocytes/pathology , Middle Aged , Monocytes/metabolism , Monocytes/pathology , Primary Myelofibrosis/pathology , Stromal Cells/metabolism , Stromal Cells/pathology , Transforming Growth Factor beta/biosynthesis
10.
Acta Haematol ; 117(4): 191-6, 2007.
Article in English | MEDLINE | ID: mdl-17170522

ABSTRACT

An untreated 66-year-old woman with chronic myelogenous leukaemia (CML) in the chronic phase was initially given imatinib mesylate, rapidly achieving a good cytogenetic response with treatment. However, acute promyelocytic leukaemia complicated by a disseminated intravascular coagulation occurred 9 months after beginning imatinib treatment. Promyelocytic crisis of CML was diagnosed by demonstration of both BCR/ABL and PML/RAR alpha chimeric genes in leukaemic cells by karyotypic and fluorescence in situ hybridization analysis. Clonal evolution with addition of the PML/RAR alpha translocation may have arisen in the early chronic phase of CML, with expansion of this clone during imatinib treatment. Promyelocytic crisis of CML is rare; furthermore, we know of no previous report of promyelocytic crisis occurring during treatment with imatinib.


Subject(s)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Piperazines/therapeutic use , Pyrimidines/therapeutic use , Aged , Antineoplastic Agents , Benzamides , Flow Cytometry , Humans , Imatinib Mesylate , Immunophenotyping , In Situ Hybridization, Fluorescence , Karyotyping , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Male , Reverse Transcriptase Polymerase Chain Reaction
11.
Acta Haematol ; 116(4): 266-71, 2006.
Article in English | MEDLINE | ID: mdl-17119328

ABSTRACT

We report a 66-year-old man with hepatitis C virus (HCV)-related cirrhosis and simultaneous hepatic relapse of non-Hodgkin's lymphoma (NHL) and of hepatocellular carcinoma (HCC). Although the liver is frequently involved by NHL, hepatic colocalization of NHL and HCC is rarely detected by imaging techniques. HCV has been suggested to be lymphotrophic as well as hepatotrophic, and therefore has attracted speculation about a causative role in some cases of lymphoma. The patient had a past history of cutaneous diffuse large B cell lymphoma (DLBCL) in concurrence with HCC 32 months previously. Complete remission (CR) had been maintained for both diseases until February 2004, when ultrasonography and computed tomography (CT) showed multiple liver tumors. Two of these, appearing hyperattenuating in the arterial phase of contrast-enhanced CT, were diagnosed histopathologically as HCC, and treated with radiofrequency ablation. The other tumors, hypoattenuating in the portal phase CT, were diagnosed histopathologically as DLBCL, and treated with cyclophosphamide, tetrahydropyranyl-Adriamycin, vincristine and prednisolone (THP-COP) in combination with rituximab. CR was achieved for both DLBCL and HCC. Given the previously demonstrated immune system tropism and perturbation by HCV, the virus might have contributed to the occurrence of the NHL as well as the HCC.


Subject(s)
Carcinoma, Hepatocellular/pathology , Liver Neoplasms/secondary , Lymphoma, Non-Hodgkin/pathology , Aged , Hepacivirus , Humans , Liver Cirrhosis , Male
12.
J Immunol ; 175(4): 2647-54, 2005 Aug 15.
Article in English | MEDLINE | ID: mdl-16081841

ABSTRACT

Hemopoietic stem and progenitor cells ordinarily residing within bone marrow are released into the circulation following G-CSF administration. Such mobilization has a great clinical impact on hemopoietic stem cell transplantation. Underlying mechanisms are incompletely understood, but may involve G-CSF-induced modulation of chemokines, adhesion molecules, and proteolytic enzymes. We studied G-CSF-induced mobilization of CD34+ CD10+ CD19- Lin- and CD34+ CD10+ CD19+ Lin- cells (early B and pro-B cells, respectively). These mobilized lymphoid populations could differentiate only into B/NK cells or B cells equivalent to their marrow counterparts. Mobilized lymphoid progenitors expressed lymphoid- but not myeloid-related genes including the G-CSF receptor gene, and displayed the same pattern of Ig rearrangement status as their bone marrow counterparts. Decreased expression of VLA-4 and CXCR-4 on mobilized lymphoid progenitors as well as multipotent and myeloid progenitors indicated lineage-independent involvement of these molecules in G-CSF-induced mobilization. The results suggest that by acting through multiple trans-acting signals, G-CSF can mobilize not only myeloid-committed populations but a variety of resident marrow cell populations including lymphoid progenitors.


Subject(s)
Granulocyte Colony-Stimulating Factor/pharmacology , Hematopoietic Stem Cell Mobilization , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/immunology , Lymphocyte Subsets/cytology , Lymphocyte Subsets/immunology , Animals , Bone Marrow Cells/cytology , Bone Marrow Cells/immunology , Bone Marrow Cells/metabolism , Cell Adhesion Molecules/biosynthesis , Cell Culture Techniques , Cell Differentiation/genetics , Cell Differentiation/immunology , Cell Lineage/genetics , Cell Lineage/immunology , Flow Cytometry , Gene Expression Profiling , Gene Rearrangement, B-Lymphocyte, Heavy Chain , Hematopoietic Stem Cell Mobilization/methods , Humans , Immunoglobulin Heavy Chains/genetics , Immunoglobulin Heavy Chains/metabolism , Immunophenotyping , Lymphocyte Count , Lymphocyte Subsets/metabolism , Mice , Mice, Inbred NOD , Mice, Knockout , Mice, SCID , Myeloid Progenitor Cells/cytology , Myeloid Progenitor Cells/immunology , Myeloid Progenitor Cells/metabolism
13.
Int J Oncol ; 26(6): 1605-12, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15870876

ABSTRACT

Recent advances in tumor immunology have resulted in identification of many epithelial cancer-related antigens and peptides applicable to specific immunotherapy. We and others have reported that several epithelial cancer-related antigens are also expressed in hematological malignancies. Two patients with hematological malignancy (multiple myeloma and chronic lymphocytic leukemia) were vaccinated with peptides derived from epithelial cancer-related antigens to evaluate the immune responses to peptides under a personalized peptide vaccination regimen. There was no adverse event except for local skin reaction at the injection site. The peptide vaccination augmented both peptide-specific CTLs cytotoxic to hematological malignant cells in post-vaccination peripheral blood mononuclear cells and peptide-specific IgG in post-vaccination sera. A transient but obvious decrease of malignant cells was observed at the early phase of the vaccination in both cases. Vaccines consisting of peptides derived from epithelial cancer antigens safely increased anti-tumor cell activity in patients with hematological malignancies. These results may provide a scientific rationale in use of epithelial cancer-related antigens for specific immunotherapy to patients with hematological malignancies.


Subject(s)
Cancer Vaccines/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Multiple Myeloma/therapy , Neoplasm Proteins/immunology , Peptides/immunology , Aged , Antibodies, Neoplasm/blood , Female , Hematopoietic Stem Cells/immunology , Humans , Immunoglobulin G/blood , Immunotherapy, Active , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Male , Middle Aged , Multiple Myeloma/immunology , T-Lymphocytes, Cytotoxic/immunology
14.
Int J Hematol ; 80(5): 428-31, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15646654

ABSTRACT

Approximately 20% of mantle cell lymphomas (MCL) present with the blastoid variant associated with poor prognosis. Lactic acidosis complicated with hematologic malignancies is seen infrequently and is associated with a poor outcome. Here we report the case of a patient with the blastoid variant of MCL complicated by lactic acidosis and who achieved complete remission through chemotherapy combined with rituximab therapy. A 77-year-old man presented with peripheral blood lymphoma cells, huge splenomegaly, abdominal and mediastinal lymphadenopathy, and pleural effusion. A bone marrow smear showed an increase in large, abnormal lymphoid cells with oval or round nuclei, distinct nucleoli, and abundant basophilic cytoplasm with vacuolization. Splenic sections also showed massive and diffuse infiltration by these cells. Flow cytometry analysis showed these cells to be positive for CD5, CD19, CD20, and kappa chain and negative for CD10 and CD23. A blastoid variant of MCL was diagnosed from the results of histologic, immunohistochemical (cyclin D1), and cytogenetic (chimeric bcl-1/IgH fusion gene) analyses. The patient recovered from the 2 episodes of severe lactic acidosis for which he had been given chemotherapy, and he achieved complete remission after subsequent chemotherapy combined with rituximab treatment.


Subject(s)
Acidosis, Lactic/pathology , Lymphoma, Mantle-Cell/pathology , Acidosis, Lactic/etiology , Aged , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Murine-Derived , Antigens, CD/blood , Antineoplastic Agents/therapeutic use , Bone Marrow/pathology , Drug Therapy, Combination , Humans , Lymphatic Diseases/etiology , Lymphatic Diseases/pathology , Lymphoma, Mantle-Cell/blood , Lymphoma, Mantle-Cell/complications , Lymphoma, Mantle-Cell/diagnostic imaging , Lymphoma, Mantle-Cell/drug therapy , Male , Radiography , Rituximab , Splenomegaly/diagnostic imaging , Splenomegaly/etiology , Splenomegaly/pathology
15.
Am J Hematol ; 73(4): 230-5, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12879424

ABSTRACT

The F-box protein Skp2 positively regulates the G1-S transition by promoting degradation of the cyclin-dependent kinase inhibitor p27(kip1) (p27). Recent evidence has suggested an oncogenic role of Skp2 in not only carcinogenesis but also lymphomagenesis. In this study, we performed immunohistochemical analysis on the cell-cycle-associated proteins, Skp2, p27, and Ki-67, in 27 patients with de novo diffuse large B-cell lymphoma (DLBCL), evaluating the correlation between the clinical characteristics and expression levels of these proteins. The patients were classified into two groups according to the positivity for Skp2 expression: a high Skp2 expression group (>60% positive for Skp2 in lymphoma cells) and a low Skp2 expression group (< or = 60%). A high level of Skp2 expression significantly correlated with advanced clinical stage (P = 0.029), although the increase did not correlate with age, gender, LDH levels, presence of extranodal disease, or performance status and resulted in no correlation with the International Prognostic Index-based risk grading. However, it was noteworthy that the high Skp2 expression group demonstrated a significantly worse prognosis than the low Skp2 expression group (P = 0.0007). The expression level of Skp2 correlated with that of Ki-67 but not necessarily with that of p27. The p27 expression level did not correlate patients' prognosis. Taken together, it was suggested that Skp2 was a valuable and independent marker predicting the outcome in DLBCL.


Subject(s)
Cell Cycle Proteins/analysis , Lymphoma, B-Cell/pathology , Lymphoma, Large B-Cell, Diffuse/pathology , Adult , Aged , Biomarkers/analysis , Female , Humans , Immunohistochemistry , Ki-67 Antigen/analysis , Lymphoma, B-Cell/mortality , Lymphoma, Large B-Cell, Diffuse/mortality , Male , Middle Aged , Prognosis , Proliferating Cell Nuclear Antigen/analysis , S-Phase Kinase-Associated Proteins , Survival Analysis , Treatment Outcome
16.
Eur J Haematol ; 71(6): 412-7, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14703690

ABSTRACT

Many hematopoietic cells undergo apoptosis when deprived of specific cytokines. Lipocalin 24p3, reported to be induced in hematopoietic cells by interleukin 3 (IL-3) depletion, induces hematopoietic cell apoptosis despite the presence of IL-3. As granulocyte colony stimulating factor (G-CSF) depletion also induces the apoptosis of G-CSF-dependent cell line cells, we examined the effect of 24p3 on the apoptotic function induced by G-CSF depletion. 24p3 was induced by the depletion of IL-3, but not G-CSF, in cytokine-dependent cell lines. Although 24p3 suppressed growth induced by IL-3, it did not influence G-CSF-dependent cell growth. These observations show that 24p3 is not involved in the G-CSF withdrawal-induced apoptosis, although it is essential in IL-3 withdrawal-induced apoptosis.


Subject(s)
Acute-Phase Proteins/physiology , Apoptosis/physiology , Granulocyte Colony-Stimulating Factor/metabolism , Hematopoietic Stem Cells/cytology , Interleukin-3/metabolism , Oncogene Proteins/physiology , Acute-Phase Proteins/analysis , Acute-Phase Proteins/genetics , Animals , Cell Differentiation , Cell Division/physiology , Cell Line , Culture Media, Conditioned , Gene Expression , Humans , Lipocalin-2 , Lipocalins , Mice , Neutrophils/cytology , Oncogene Proteins/analysis , Oncogene Proteins/genetics , Polymerase Chain Reaction , Proto-Oncogene Proteins , Recombinant Proteins
17.
J Immunol ; 169(9): 4707-11, 2002 Nov 01.
Article in English | MEDLINE | ID: mdl-12391177

ABSTRACT

IFN-alpha inhibits B lymphocyte development, and the nuclear protein Daxx has been reported to be essential for this biological activity. We show in this study that IFN-alpha inhibits the clonal proliferation of B lymphocyte progenitors in response to IL-7 in wild-type, but not in tyk2-deficient, mice. In addition, the IFN-alpha-induced up-regulation and nuclear translocation of Daxx are completely abrogated in the absence of tyk2. Therefore, tyk2 is directly involved in IFN-alpha signaling for the induction and translocation of Daxx, which may result in B lymphocyte growth arrest and/or apoptosis.


Subject(s)
B-Lymphocytes/cytology , B-Lymphocytes/enzymology , Carrier Proteins/metabolism , Growth Inhibitors/physiology , Immunosuppressive Agents/pharmacology , Interferon-alpha/physiology , Intracellular Signaling Peptides and Proteins , Nuclear Proteins/metabolism , Protein-Tyrosine Kinases/physiology , Proteins/physiology , Active Transport, Cell Nucleus/genetics , Active Transport, Cell Nucleus/immunology , Animals , B-Lymphocytes/immunology , Bone Marrow Cells/cytology , Bone Marrow Cells/enzymology , Bone Marrow Cells/immunology , Carrier Proteins/biosynthesis , Carrier Proteins/physiology , Cell Differentiation/genetics , Cell Differentiation/immunology , Cell Line , Cells, Cultured , Co-Repressor Proteins , Coculture Techniques , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/enzymology , Hematopoietic Stem Cells/immunology , Interleukin-7/antagonists & inhibitors , Interleukin-7/physiology , Mice , Mice, Knockout , Molecular Chaperones , Nuclear Proteins/biosynthesis , Nuclear Proteins/physiology , Protein-Tyrosine Kinases/deficiency , Protein-Tyrosine Kinases/genetics , Proteins/genetics , TYK2 Kinase
SELECTION OF CITATIONS
SEARCH DETAIL
...